mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + Tremelimumab
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Cancers
Conditions
Biliary Tract Cancers
Trial Timeline
May 27, 2025 → May 1, 2029
NCT ID
NCT06564623About mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + Tremelimumab
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + Tremelimumab is a phase 1 stage product being developed by AstraZeneca for Biliary Tract Cancers. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06564623. Target conditions include Biliary Tract Cancers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06564623 | Phase 1 | Recruiting |
Competing Products
20 competing products in Biliary Tract Cancers